Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kamada makes management changes

This article was originally published in Scrip

Executive Summary

Kamada, a plasma-derived protein therapeutics company focused on orphan indications, has announced executive management changes intended to strengthen the company's leadership. Under the changes, David Tsur, co-founder and CEO, will become deputy executive chair of the board, a new position whereby he will maintain his strategic advisory role yet relinquish day-to-day management responsibilities. Leon Recanti will remain the chair of the board. Amir London, the company's senior vice-president of business development, will become CEO and Gil Efron, currently chief financial officer, will take on the added role of deputy CEO. The changes are expected to go into effect in July 2015.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts